Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocular TherapeutixOCUL -4.73%55 Debt-to-Equity is 0.15 as of Jun. 2026, which is 66% below its 10-year median of 0.44. GuruFocus rates OCUL with a GF Score™ of 55/100 and a GF Value™ of $4.56 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Ocular Therapeutix ranks better than 51.62% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ocular Therapeutix's Debt-to-Equity or its related term are showing as below:
OCUL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -16.35 Med: 0.44 Max: 20.98
Current: 0.15
During the past 13 years, the highest Debt-to-Equity Ratio of Ocular Therapeutix was 20.98. The lowest was -16.35. And the median was 0.44.
OCUL's Debt-to-Equity is ranked better than 51.62% of 959
companies
in the Biotechnology industry
Industry Median: 0.15
vs OCUL: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ocular Therapeutix Debt-to-Equity Related Terms
Ocular Therapeutix Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCUL vs KARD, GHRS, FTRE: Debt-to-Equity Comparison
For the Biotechnology subindustry, Ocular Therapeutix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (OCUL) has a Debt-to-Equity of 0.15 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ocular Therapeutix and its competitors. This is 66% below median its historical median of 0.44. According to the industry distribution chart, Ocular Therapeutix ranks #464 out of 959 companies in the Biotechnology industry, placing it in the top 48.4%.
Is Ocular Therapeutix's Debt-to-Equity too high?
Ocular Therapeutix's current Debt-to-Equity of 0.15 is 66% below median its 10-year median of 0.44. The Biotechnology industry median Debt-to-Equity is 0.15. Ocular Therapeutix's value of 0.15 is 0% at this industry median. Based on the distribution chart, Ocular Therapeutix ranks #464 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Debt-to-Equity compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #464 out of 959 companies for Debt-to-Equity. This puts Ocular Therapeutix in the upper half of its industry. The industry median Debt-to-Equity is 0.15. Ocular Therapeutix's value of 0.15 is 0% at this benchmark. While the company's 10-year median is 0.44 vs. the industry median of 0.15, Ocular Therapeutix has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocular Therapeutix's current Debt-to-Equity of 0.15 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current Debt-to-Equity is 0.15, which is 66% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (OCUL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.56, compared to a current price of $11.19 — trading 145.3% above its estimated fair value. The current Debt-to-Equity is 0.15, which is 66% below median its 10-year median of 0.44 and 0% at the Biotechnology industry median of 0.15. Ocular Therapeutix's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ocular Therapeutix (OCUL), the current Debt-to-Equity is 0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (OCUL) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of $11.19 is trading 145.3% above its estimated GF Value™ of $4.56.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for OCUL:
Debt-to-Equity: 0.15 (66% below median its 10-year median of 0.44)
GF Value™: $4.56 vs. price of $11.19 (145.3% above fair value)
Industry Position: 0% at the Biotechnology median (#464 of 959)
No single metric tells the full story. See the OCUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
55GF Score
Get the complete analysis for OCUL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUL has been successfully added to your 
